
The study addresses Acute Respiratory Distress Syndrome (ARDS), proposing a novel pharmacological approach targeting the microtubule accessory factor EB3. Utilizing the CIPRI peptide to disrupt EB3–IP3R3 interaction, the treatment showed efficacy in mitigating calcium release, preserving endothelial junctions, and reducing inflammation-induced lung injury. This promising strategy presents potential for managing microvascular hyperpermeability.
Like
Save
Share